{'fraction_non_alphanumeric': 0.03636363636363636, 'fraction_numerical': 0.0, 'mean_word_length': 6.481481481481482, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Longitudinal regret after treatment for low‐ and intermediate‐risk prostate cancer

Prostate cancer patients diagnosed with low‐ and intermediate‐risk disease have several treatment options. Decisional regret after treatment is a concern, especially when poor oncologic outcomes or declines in health‐related quality of life (HRQoL) occur. This study assessed determinants of longitudinal decisional regret in prostate cancer patients attending a multidisciplinary clinic and treated with radical prostatectomy (RP), external beam radiation therapy (EBRT), brachytherapy (BT), or active surveillance (AS).